Holen Sie sich die Stockscreener-App
66.85
0.01%
-0.01
Handel nachbörslich:
66.85
Schlusskurs vom Vortag:
$66.86
Offen:
$69.725
24-Stunden-Volumen:
582.18K
Relative Volume:
0.89
Marktkapitalisierung:
$2.55B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-212.18M
KGV:
-11.16
EPS:
-5.9897
Netto-Cashflow:
$-181.33M
1W Leistung:
-3.44%
1M Leistung:
-6.86%
6M Leistung:
-25.51%
1J Leistung:
+39.01%
1-Tages-Spanne:
$65.78
$69.72
1-Wochen-Bereich:
$65.78
$72.35
52-Wochen-Spanne:
$40.00
$99.50
Disc Medicine Inc Stock (IRON) Company Profile
Firmenname
Disc Medicine Inc
Sektor
Branche
Telefon
(617) 674-9274
Adresse
321 ARSENAL STREET, SUITE 101, WATERTOWN
Compare IRON vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IRON
Disc Medicine Inc
|
66.85 | 2.55B | 0 | -212.18M | -181.33M | -5.9897 |
VRTX
Vertex Pharmaceuticals Inc
|
436.58 | 110.90B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
629.68 | 73.20B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
776.26 | 49.71B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.27 | 38.32B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
144.37 | 30.97B | 742.00K | -1.37B | -1.07B | -7.0731 |
Disc Medicine Inc Stock (IRON) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-03 | Fortgesetzt | Stifel | Buy |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-06-11 | Fortgesetzt | Raymond James | Strong Buy |
| 2025-02-27 | Eingeleitet | TD Cowen | Buy |
| 2024-11-05 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-11-04 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-10-23 | Eingeleitet | Jefferies | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-08-22 | Eingeleitet | Wells Fargo | Overweight |
| 2024-04-01 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2023-12-19 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-06-09 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-06-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-05-17 | Eingeleitet | Raymond James | Outperform |
| 2023-04-28 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-04-21 | Eingeleitet | Stifel | Buy |
| 2023-04-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2023-03-23 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-02-28 | Eingeleitet | SVB Securities | Outperform |
Alle ansehen
Disc Medicine Inc Aktie (IRON) Neueste Nachrichten
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action InvestigationIRON - Carroll County Mirror-Democrat
UBS Group AG Reduces Holdings in Disc Medicine, Inc. $IRON - MarketBeat
Should Disc Medicine’s RALLY-MF Data and Wider Pipeline Reveal a Pivotal Inflection for IRON’s Narrative? - simplywall.st
Disc Medicine, Inc.Common Stock (NQ: IRON - FinancialContent
IRON Maintained by Morgan Stanley -- Price Target Raised to $80. - GuruFocus
Cantor Fitzgerald Remains a Buy on Disc Medicine (IRON) - The Globe and Mail
Morgan Stanley Raises Price Target on Disc Medicine to $80 From $75, Keeps Overweight Rating - marketscreener.com
Understanding Momentum Shifts in (IRON) - Stock Traders Daily
IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are ... - Caledonian Record
IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewswire Inc.
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inqui - GuruFocus
Disc Medicine, Inc. Announces Oral Presentation of Phase 2 RALLY-MF Trial Data for DISC-0974 at EHA 2026 Congress and Corporate Update Call - Quiver Quantitative
Experimental anemia treatment shows 70% response in myelofibrosis trial - Stock Titan
Vanguard Group Inc. Acquires 319,621 Shares of Disc Medicine, Inc. $IRON - MarketBeat
Stifel Maintains Disc Medicine(IRON.US) With Buy Rating, Maintains Target Price $111 - Moomoo
Hear Disc Medicine leaders in two live investor conference webcasts - Stock Titan
Disc Medicine to Participate in Upcoming Investor Conferences - FinancialContent
Number of shareholders of Disc Medicine, Inc. – NASDAQ:IRON - TradingView
A Look At Disc Medicine (IRON) Valuation As Key APOLLO Phase 3 And Pipeline Milestones Progress - Sahm
Disc Medicine, Inc. (IRON) Eps Diluted (TTM) - Zacks Investment Research
HC Wainwright Cuts Earnings Estimates for Disc Medicine - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.IRON - PR Newswire
Disc Medicine FY2030 EPS Forecast Raised by HC Wainwright - MarketBeat
H.C. Wainwright Maintains Disc Medicine(IRON.US) With Buy Rating, Maintains Target Price $118 - Moomoo
BMO Capital Maintains Disc Medicine(IRON.US) With Buy Rating, Maintains Target Price $100 - Moomoo
Truist Financial Maintains Disc Medicine(IRON.US) With Buy Rating, Maintains Target Price $83 - Moomoo
A Look At Disc Medicine (IRON) Valuation After Legal Probes And FDA Complete Response Letter - Yahoo Finance
Press releases provided by CNW - Techaeris
Disc Medicine Q1 Net Loss Widens - Moomoo
Disc Medicine (NASDAQ:IRON) Releases Quarterly Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat
Earnings Flash (IRON) Disc Medicine Posts Q1 Net Loss $1.65 a Share, vs. FactSet Est of $1.65 Loss - marketscreener.com
Disc Medicine (NASDAQ: IRON) posts wider Q1 loss but holds $730M cash - Stock Titan
Disc Medicine 1Q 2026: Net income $(63.5M), EPS $(1.65) — 10-Q Summary - TradingView
Earnings Flash (IRON) Disc Medicine Posts Q1 Net Loss $1.65 a Share, Vs. FactSet Est of $1.65 Loss - Moomoo
IRON: Phase 3 bitopertin trial enrollment completed; strong cash position supports pipeline into 2029 - TradingView
Disc Medicine finishes Phase 3 rare-disease trial, eyes Q4 data - Stock Titan
IRON: Net loss widened to $63.5M in Q1 2026 as bitopertin's FDA review was delayed for more data - TradingView
Disc Medicine (NASDAQ: IRON) posts Q1 2026 loss and advances late-stage trials - Stock Titan
How Investors Are Reacting To Disc Medicine (IRON) After FDA Letter Triggers Shareholder Investigation - simplywall.st
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action InvestigationIRON - TMX Newsfile
Avoiding Lag: Real-Time Signals in (IRON) Movement - Stock Traders Daily
Disc Medicine, Inc. $IRON Shares Acquired by Universal Beteiligungs und Servicegesellschaft mbH - MarketBeat
Jennison Associates LLC Takes Position in Disc Medicine, Inc. $IRON - MarketBeat
Pictet Asset Management Holding SA Grows Stock Holdings in Disc Medicine, Inc. $IRON - MarketBeat
Disc Medicine (IRON) Projected to Post Earnings on Thursday - MarketBeat
ROSEN, LEADING INVESTOR COUNSEL, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action InvestigationIRON - TMX Newsfile
IRON Investor News: If You Have Suffered Losses in Disc - GlobeNewswire
[ARS] Disc Medicine, Inc. SEC Filing - Stock Titan
Disc Medicine (NASDAQ: IRON) details 2026 proxy, pay and board votes - Stock Titan
ROSEN, A LONGSTANDING LAW FIRM, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action InvestigationIRON - TMX Newsfile
Disc Medicine prices upsized securities offering to raise total $250M - MSN
Finanzdaten der Disc Medicine Inc-Aktie (IRON)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.53%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):